The right drugs at the right time for the right patient

The MD Anderson precision oncology decision support platform

Amber Johnson, Jia Zeng, Ann M. Bailey, Vijaykumar Holla, Beate Litzenburger, Humberto Lara-Guerra, Gordon Mills, John Mendelsohn, Kenna R. Shaw, Funda Meric-Bernstam

Research output: Contribution to journalReview article

29 Citations (Scopus)

Abstract

The development of resources for clinical interpretation of cancer-associated genetic alterations has significantly lagged behind the technical developments enabling their detection in a time- and cost-efficient manner. The lack of scientific and informatics decision support for oncologists can lead to no action being taken or suboptimal therapeutic choices being made, which could affect the clinical outcome of a patient as well as convoluting research findings from clinical trials. In this article, we describe the precision oncology decision support (PODS) platform developed within The Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy (IPCT) at MD Anderson Cancer Center; the platform aims to bridge the gap between molecular alteration detection and identification of appropriate treatments.

Original languageEnglish (US)
Pages (from-to)1433-1438
Number of pages6
JournalDrug Discovery Today
Volume20
Issue number12
DOIs
StatePublished - Dec 1 2015
Externally publishedYes

Fingerprint

Patient Rights
Pharmaceutical Preparations
Neoplasms
Informatics
Therapeutics
Clinical Trials
Costs and Cost Analysis
Research

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

Johnson, A., Zeng, J., Bailey, A. M., Holla, V., Litzenburger, B., Lara-Guerra, H., ... Meric-Bernstam, F. (2015). The right drugs at the right time for the right patient: The MD Anderson precision oncology decision support platform. Drug Discovery Today, 20(12), 1433-1438. https://doi.org/10.1016/j.drudis.2015.05.013

The right drugs at the right time for the right patient : The MD Anderson precision oncology decision support platform. / Johnson, Amber; Zeng, Jia; Bailey, Ann M.; Holla, Vijaykumar; Litzenburger, Beate; Lara-Guerra, Humberto; Mills, Gordon; Mendelsohn, John; Shaw, Kenna R.; Meric-Bernstam, Funda.

In: Drug Discovery Today, Vol. 20, No. 12, 01.12.2015, p. 1433-1438.

Research output: Contribution to journalReview article

Johnson, A, Zeng, J, Bailey, AM, Holla, V, Litzenburger, B, Lara-Guerra, H, Mills, G, Mendelsohn, J, Shaw, KR & Meric-Bernstam, F 2015, 'The right drugs at the right time for the right patient: The MD Anderson precision oncology decision support platform', Drug Discovery Today, vol. 20, no. 12, pp. 1433-1438. https://doi.org/10.1016/j.drudis.2015.05.013
Johnson, Amber ; Zeng, Jia ; Bailey, Ann M. ; Holla, Vijaykumar ; Litzenburger, Beate ; Lara-Guerra, Humberto ; Mills, Gordon ; Mendelsohn, John ; Shaw, Kenna R. ; Meric-Bernstam, Funda. / The right drugs at the right time for the right patient : The MD Anderson precision oncology decision support platform. In: Drug Discovery Today. 2015 ; Vol. 20, No. 12. pp. 1433-1438.
@article{73f954b6126240f2b8c01ce1ffa78f99,
title = "The right drugs at the right time for the right patient: The MD Anderson precision oncology decision support platform",
abstract = "The development of resources for clinical interpretation of cancer-associated genetic alterations has significantly lagged behind the technical developments enabling their detection in a time- and cost-efficient manner. The lack of scientific and informatics decision support for oncologists can lead to no action being taken or suboptimal therapeutic choices being made, which could affect the clinical outcome of a patient as well as convoluting research findings from clinical trials. In this article, we describe the precision oncology decision support (PODS) platform developed within The Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy (IPCT) at MD Anderson Cancer Center; the platform aims to bridge the gap between molecular alteration detection and identification of appropriate treatments.",
author = "Amber Johnson and Jia Zeng and Bailey, {Ann M.} and Vijaykumar Holla and Beate Litzenburger and Humberto Lara-Guerra and Gordon Mills and John Mendelsohn and Shaw, {Kenna R.} and Funda Meric-Bernstam",
year = "2015",
month = "12",
day = "1",
doi = "10.1016/j.drudis.2015.05.013",
language = "English (US)",
volume = "20",
pages = "1433--1438",
journal = "Drug Discovery Today",
issn = "1359-6446",
publisher = "Elsevier Limited",
number = "12",

}

TY - JOUR

T1 - The right drugs at the right time for the right patient

T2 - The MD Anderson precision oncology decision support platform

AU - Johnson, Amber

AU - Zeng, Jia

AU - Bailey, Ann M.

AU - Holla, Vijaykumar

AU - Litzenburger, Beate

AU - Lara-Guerra, Humberto

AU - Mills, Gordon

AU - Mendelsohn, John

AU - Shaw, Kenna R.

AU - Meric-Bernstam, Funda

PY - 2015/12/1

Y1 - 2015/12/1

N2 - The development of resources for clinical interpretation of cancer-associated genetic alterations has significantly lagged behind the technical developments enabling their detection in a time- and cost-efficient manner. The lack of scientific and informatics decision support for oncologists can lead to no action being taken or suboptimal therapeutic choices being made, which could affect the clinical outcome of a patient as well as convoluting research findings from clinical trials. In this article, we describe the precision oncology decision support (PODS) platform developed within The Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy (IPCT) at MD Anderson Cancer Center; the platform aims to bridge the gap between molecular alteration detection and identification of appropriate treatments.

AB - The development of resources for clinical interpretation of cancer-associated genetic alterations has significantly lagged behind the technical developments enabling their detection in a time- and cost-efficient manner. The lack of scientific and informatics decision support for oncologists can lead to no action being taken or suboptimal therapeutic choices being made, which could affect the clinical outcome of a patient as well as convoluting research findings from clinical trials. In this article, we describe the precision oncology decision support (PODS) platform developed within The Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy (IPCT) at MD Anderson Cancer Center; the platform aims to bridge the gap between molecular alteration detection and identification of appropriate treatments.

UR - http://www.scopus.com/inward/record.url?scp=84949534750&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949534750&partnerID=8YFLogxK

U2 - 10.1016/j.drudis.2015.05.013

DO - 10.1016/j.drudis.2015.05.013

M3 - Review article

VL - 20

SP - 1433

EP - 1438

JO - Drug Discovery Today

JF - Drug Discovery Today

SN - 1359-6446

IS - 12

ER -